Pioneers in Immunoregulatory Drug Discovery and Development
We develop novel immunoregulatory therapeutics for patients with autoimmune diseases, starting with ulcerative colitis and Crohn’s disease.
Our Mission
Our management team has significant public and private biotech company experience in the development of immunoregulatory drugs and a proven track record in raising capital, IPO and M&A for effectively accelerating drug candidates into and through late-stage clinical development. We are on a mission to develop safer and more effective therapeutics that address the unmet needs of patients with inflammatory and autoimmune diseases.
Press and Articles from NImmune
The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science
Download Press Release TITAN-X Precision Medicine A.I. Platform identifies therapeutic targets and successfully fueled development of expansible pipelines with leading therapeutic assets in Phase 1-3 clinical testing Integrates A.I., bioinformatics and advanced...
NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025
The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for inflammatory and autoimmune diseases, will present results from two novel studies for omilancor, a once-daily, oral, best- and first-in-class therapy in Phase 3 clinical development for ulcerative colitis (“UC”) and Phase 2 for Crohn’s disease, at Digestive Disease Week 2025. DDW 2025 will be held at the San Diego Convention Center from May 3-6, 2025.
The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science
Download Press Release First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral NIM-1324 treatment confirmed as well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 validated to engage LANCL2 in...
NImmune Leadership Team
A highly experienced and talented team with deep knowledge of LANCL therapeutics and a proven track record of biotech industry success.
Product Candidates
NImmune’s clinical development pipeline includes first- and best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases with multiple catalyst milestones in the next 12 months. Lead clinical candidate omilancor, an oral, once-daily, gut-restricted, first-in-class LANCL2 therapeutic is in Phase 3 clinical development for ulcerative colitis and Phase 2 clinical development for Crohn’s disease, with multiple I&I indications planned. Topline Phase 3 data readout expected in 2026.
Learn more about the omilancor story, LANCL2 mechanism of action, and the market opportunity we seek to address.
Contact Us
If you would like to know more about our research, please fill out the form below.